



The
Patent
Office

PCT/EP 99 / 06298

0 - DG 1
27. 08. 1999



(41)

INVESTOR IN PEOPLE

EP 99 / 6298

REC'D 04 OCT 1999	
WIPO	PCT

09/786998

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ


PRIORITY DOCUMENT
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH
RULE 17.1(a) OR (b)

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.


Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



L. Mahoney

Signed

Dated 29 July 1999



The
Patent
Office



15SEP98 E390178-1 D00192
P01/7700 25.00 - 9820012.4

The Patent Office

Cardiff Road
Newport
Gwent NP9 1RH

Request for grant of a patent

(See notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form))

1. Your reference

P.75336 GCW.CMK

14 SEP 1998

2. Patent application number

(The Patent Office will fill in this part)

9820012.4

3. Full name, address and postcode of the or of each applicant (underline all surnames)

Pharmacia & Upjohn S.p.A.
Via Robert Koch 1.2
20152 Milan
Italy

Patents ADP number (if you know it)

7100001001

If the applicant is a corporate body, give the country/state of its incorporation

4. Title of the invention

USE OF AN ANTHRACYCLINE DERIVATIVE FOR THE TREATMENT OF A LIVER TUMOR.

5. Name of your agent (if you have one)

J A KEMP & CO

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

14 SOUTH SQUARE
GRAY'S INN
LONDON WC1R 5LX

26001

Patents ADP number (if you know it)

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application number
(if you know it)

Date of filing
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing
(day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer "Yes" if:


Yes

- a) any applicant named in part 3 is not an inventor, or
 - b) there is an inventor who is not named as an applicant, or
 - c) any named applicant is a corporate body:
- See note (d))

Patents Form 1/77

9. Enter the number of sheets for all the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

 Description 11
Claim(s) 2
Abstract 1
Drawing(s)

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for preliminary examination and search (Patents Form 9/77)

Request for substantive examination (Patents Form 10/77)

Any other documents (please specify)

11. I/We request the grant of a patent on the basis of this application

Signature  Date 14 September 1998

12. Name and daytime telephone number of person to contact in the United Kingdom C M KEEN
0171 405 3292

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- a) If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- b) Write your answers in capital letters using black ink or you may type them.
- c) If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- d) If you have answered "Yes" Patents Form 7/77 will need to be filed.
- e) Once you have filled in the form you must remember to sign and date it.
- f) For details of the fee and ways to pay please contact the Patent Office.

USE OF AN ANTHRACYCLINE DERIVATIVE FOR THE TREATMENT OF A
LIVER TUMOR

5 The present invention relates to the use of methoxymorpholino
doxorubicin for the treatment of a liver cancer; in
particular, it refers to the intrahepatic administration of
~~methoxymorpholino doxorubicin for use in the liver tumor~~
therapy.

10 Methoxymorpholino doxorubicin (MMDX) is a new doxorubicin
derivative obtained with the substitution of the -NH₂ at
position 3' in the sugar moiety with a methoxymorpholino
group. The compound was synthesized in the course of a
research program aimed at identifying new anthracyclines with
15 at least partially novel modes of action, and possessing
broad spectrum of activity, including activity on multidrug
resistant (mdr) tumors.

MMDX is active *in vitro* and *in vivo* on tumor cells resistant
to anthracyclines and presenting the mdr phenotype, this last
20 mechanism being recognized to occur also in man.

No cross-resistance was observed on tumor cells resistant to
L-PAM or cDDP, or on cells resistant to Topoisomerase II
inhibitors (at-mdr).

MMDX is active after i.p., i.v. or oral administration, with
25 good antitumor activity on murine leukemias, and on solid
murine and human tumor models.

The compound differs from most anthracyclines in being highly
potent when administered *in vivo*, the optimal i.v. dose being
at least 80 fold less than that of doxorubicin. This result,
30 and the observation that the cytotoxic activity of MMDX is
increased *in vitro* in the presence of rat and human liver
microsomes, suggest that MMDX may be transformed into highly
cytotoxic metabolite(s).

A well known pathway of the metabolic transformation of the antitumor anthracyclines in mammals is the side-chain carbonyl group reduction, giving the corresponding 13-dihydroderivative. The reduced derivative of MMDX maintains activity *in vitro* and *in vivo* against doxorubicin-resistant models, at doses however 10 fold higher as compared to the parent drug.

~~The high lipophilicity of the molecule, which confers to the~~

compound the ability to reach high intracellular concentrations and is most likely one of the reasons of its efficacy on resistant models, makes it effective also after oral administration. The oral antitumor efficacy of MMDX has been examined in a panel of different tumor types with various schedules of administration. The results demonstrate that the oral treatment with MMDX is associated, in all the animal models examined, with an antitumor activity comparable to that observed after intravenous (i.v.) administration. In these models, the effective oral doses of MMDX are 1.3-2 fold higher than the effective i.v. doses. In particular, in liver metastases from M5076 murine fibrosarcoma, the best result (doubling of survival time) was achieved with the oral formulation, administered daily for 5 days; the injectable formulation was less effective. This might be a reflection of a different behaviour of the drug, due to first pass effect to the liver.

It is well known that there is currently no effective conventional treatment for patient with primary hepatocellular carcinoma (HCC) and cholangiocarcinoma invading the liver.

In addition, the liver is a common site of metastasis in many human cancers.

Primary Liver Cancer

Tumors of the liver are among the most common malignancies in the world. The annual international incidence of the disease

is approximately 1 million cases, with a male to female ratio of approximately 4:1. There are 1.2 million deaths per year world wide. There is a huge geographic variation incidence corresponding to 2/100,000 in North America to 30/100,000 in South East Asia, although these numbers refers often to "total liver cancer", without a differentiation between primary and secondary.

~~The highest incidence of liver cancer is seen in the Far East~~

and is associated with high endemic hepatitis B carrier rates, contamination of foodstuffs, stored grains, drinking water and soil. Advances in the management of these malignancies will likely depend on immunization strategies for hepatitis B and C and on developing a means of decreasing cirrhosis of any origin. Cirrhosis is frequently associated with HCC, especially in Europe and USA. Systemic chemotherapy is generally disappointing, with response rate averaging less than 20%. Anthracyclines remain the most widely used agents. Mitomycin C is also used.

A wide variety of both surgical and nonsurgical therapies have become available for HCC. Surgical resection and orthotopic transplantation are the only curative options, but it is estimated that less than 10% of patients are suitable for this approach and long-term results are poor. The low resectability and the high recurrent rate (40% in five years after surgery), together with the fact that HCC tends to be fatal because of local hepatic progression rather than widespread metastasis, stimulated the development of several locoregional therapeutic approaches, including intra-arterial chemotherapy. Higher response rates appear to be reported for intra hepatic artery (IHA) chemotherapy administered along with embolizing agents, such as lipiodol, gel foam and degradable starch microspheres. This approach is increasingly used in the Far East. Anthracyclines (doxorubicin and epirubicin are widely used in this setting. However, no

substantial improvement in survival is obtained with current chemotherapeutic attempts. The need for new effective treatments remains high.

Secondary Liver Cancer

5 Liver is a common site of metastasis in many human cancers and hepatic involvement is often the major cause of morbidity and mortality in disseminated malignancy. In particular, the liver, by virtue of the portal venous drainage system, is usually the first - and may be the only -
10 site of metastases in many patients with primary colorectal cancer. Gastric and pancreatic cancer - but also melanoma, lung and breast cancers - may also frequently metastasize to the liver. Metastatic liver tumors are often the first evidence of the progression of a patient's cancer, and
15 particularly in colorectal cancer are the only tumors detected. Colorectal carcinoma is a disease of industrialized nations. It is estimated that in USA over 160,000 new cases were diagnosed yearly and that 75,000 deaths occurred as a result of the advanced disease. Epidemiological studies show
20 that the incidence of colorectal carcinoma is increasing. Involvement of the liver is found in 40-70% of patients with progressive disease and is the sole site of initial tumor recurrence in up to 30% of patients with metastatic disease. Left untreated, metastatic lesions to the liver from
25 colorectal cancers are associated with survival of 3 to 24 months.

For patients with isolated liver metastases, surgical resection is the best treatment option, with 20-30% 5 year survival rate. Surgery is only possible in about 10% of cases
30 and it is estimated that up to 25% of patients undergoing surgical resection will recur with metastatic liver cancer. Palliation with systemic chemotherapy is currently offered to most patients with extensive or multiple liver metastases. To date, systemic 5-fluoruracil (5-FU) plus folinic acid is

considered the optimum treatment for metastatic colorectal cancer, yielding response rates of only 20% and overall survival of around 12 months. Irinotecan is the standard treatment after failure of 5-FU leucovorin, with a response rate of 15% and median survival time of approximately 9 months. Clinical trials are ongoing with the objective to determine the role of irinotecan as first-line treatment in combination with 5-FU leucovorin.

In case the disease is confined to the liver and it is inoperable, regional intraarterial chemotherapy may be indicated. With the hepatic arterial infusion of 5-FU or of its analogue, 5-fluorodeoxyuridine (FUDR) attempts have been made to maximise the clinical outcome (response rate in up to 50% of cases) but with no substantial effect on survival. MMDX represents a therapeutic option in the treatment of a liver cancer.

The expectation that MMDX is effective in liver neoplasms comes from the findings of phase I and phase Ib studies conducted by intravenous route, where, out of 30 patients evaluable for response in liver, 5 experienced regressions of liver metastases. Two patients with colorectal cancer had a <50% regression of liver lesions after 3 cycles, two patients with renal cancer showed a regression greater than 50% in liver lesions after 3 cycles of treatment and an additional patient with colorectal cancer and multiple liver metastases at entry (subsequently dead from pulmonary embolism after the

first cycle of treatment) showed no evidence of liver metastases at autopsy. Tumor shrinkage occurred at doses of 1250 and 1500 mcg/m² i.v. Main toxicities were nausea and vomiting (requiring intravenous antiemetic treatment), myelosuppression and transient elevations in transaminases.

In addition, in an ongoing phase II study by i.v. route in breast cancer patients with liver metastases (previously untreated for the advanced disease), 1 complete response and

3 partial responses (one of them not confirmed four weeks apart) were observed in liver lesions of four patients treated so far (at 1500 mcg/m² i.v.).

These findings suggest an interesting affinity of MMDX for liver lesions, even in tumor types resistant to conventional chemotherapy such as colorectal cancer and renal cancer.

Strong evidence of antitumor efficacy in liver is also supported by preclinical data. Activity of MMDX against liver

metastases from M5076 murine reticulosarcoma is higher after oral administration as compared to the i.v. route, suggesting that a first pass effect may favour the efficacy in liver. In addition, MMDX administered orally is more effective on the liver metastases than on the solid primary in the same model. This specific effect on liver metastases is probably due to metabolite(s) produced by liver enzymes. This hypothesis is reinforced by several results showing MMDX (PNU 152243) being activated in vitro by liver microsomes to a highly cytotoxic product. This metabolic conversion is believed to occur also in humans.

The hints of activity observed in the current clinical experience, coupled with the activity of MMDX in mdr models and in liver metastasis models, raise the expectation of an improved clinical outcome for patients with hepatic neoplastic lesions.

It would be therefore desirable to establish drug delivery strategies to avoid the high i.v. dosages of MMDX presently believed to have an antitumor activity at the hepatic level and to improve the antitumor efficacy of MMDX against a primary liver cancer and liver metastases.

There is a need to achieve high MMDX concentration at the hepatic tumor site, while reducing systemic exposure and hence toxicity.

The present invention fulfills such a need by providing a new method for administration of MMDX to a patient suffering from

a liver tumor which reduces the MMDX amount without decreasing the MMDX's antitumor activity at the hepatic tumor site by directly injecting MMDX into the hepatic artery.

It is therefore a first object of the present invention the use of MMDX in the preparation of a medicament for the treatment of a human liver tumor which comprises intrahepatic administration of MMDX.

~~It is a further object of the present invention a method of~~
treating a human liver tumor which comprises the intrahepatic administration of a therapeutically effective amount of MMDX to a patient in need thereof.

According to the present invention, a liver tumor can be a tumor primarily confined to the liver such as, e.g. an hepatocellular carcinoma or a cholangiocarcinoma, or a liver metastase.

Preferably, the intrahepatic administration of MMDX is performed via the hepatic artery.

In a particular embodiment of the invention, MMDX is administered via the hepatic artery as an infusion of about 15 minutes to about 30 minutes every 4 weeks to adult patients with either a hepatic metastatic cancer, for example, patients with colorectal cancer who have progressed after receiving intravenous chemotherapy or intrahepatic 5-fluorouracil or 5-fluorodeoxyuridine (FUDR) chemotherapy, or with previously untreated primary liver carcinoma such as, for example, hepatocellular carcinoma or cholangiocarcinoma

involving the liver.

In a more particular embodiment of the present invention, MMDX is administered to a patient in a dosage ranging from about 100 mcg/m² to about 800 mcg/m², for example in a dosage of about 200 mcg/m².

In a still more particular embodiment of the present invention, the appropriate dose of MMDX, preferably previously dissolved in saline solution, is mixed with a

suitable amount, for example 7 ml, of an agent, for example iodized oil (LIPIODOL®), which remains selectively in a liver tumor after its injection through the hepatic artery.

LIPIODOL® is a lipid lymphographic agent which has been found to remain selectively in liver tumor after its injection through the hepatic artery so it is particularly useful as a carrier of anticancer agents.

The administration dosage of MMDX will vary depending upon the disease status of the patient.

The dosage regimen must therefore be tailored to the particular of the patient's conditions, response and associate treatments in a manner which is conventional for any therapy, and may need to be adjusted in response to changes in conditions and/or in light of other clinical conditions.

For example, for intrahepatic therapy, freeze-dried vials containing 500 mcg of MMDX is diluted with 5 ml of sterile saline for injection to obtain a MMDX concentration of 100 mcg/ml. The appropriate dose of MMDX to be given to the patient is optionally mixed with a suitable amount of LIPIODOL®.

The active drug can be administered directly into the lateral entry of an i.v. line inserted into the bung of an intrahepatic portacath lying beneath the upper anterior abdominal wall. The drug can be administered, for example, over 30 minutes infusion in a volume of 100 ml of normal saline.

Flushing of the device with 10-20 ml of saline can be done to assure that all the drug is given. Patients who do not have a portacath have a catheter inserted into the hepatic artery by a femoral Seldinger approach and the drug can be infused, for example, over 30 minutes infusion in a volume of 100 ml of normal saline. The catheter is inserted under local anesthesia and can then be removed from the groin, a pressure

bandage applied and nursing observations continued overnight in hospital.

Object of this invention is also to provide a pharmaceutical composition comprising MMDX or a pharmaceutically acceptable salt thereof, as the active substance, in association with a pharmaceutically acceptable agent which remains selectively in a liver tumor after its intrahepatic injection, for

~~example through the hepatic artery, and one or more~~

pharmaceutically acceptable excipients and/or carriers. The

pharmaceutical compositions are usually prepared following conventional methods and are administered in a pharmaceutically suitable form. For instance, solutions for intrahepatic injection or infusion may contain as a carrier, for example, sterile water or preferably, they may be in the form of sterile aqueous isotonic saline solutions.

The following Experimental Protocol illustrates but do not limit the present invention.

EXPERIMENTAL PROTOCOL

A single arm, multicentre, dose-finding Phase I study of methoxymorpholino doxorubicin (PNU 152243) administered as a brief infusion of 30 minutes every 4 weeks via the hepatic artery (IHA) to adult patients either with hepatic metastatic colorectal cancer who have progressed after receiving intravenous chemotherapy or intrahepatic 5-fluoruracil chemotherapy, or with previously untreated primary hepatocellular carcinoma or cholangiocarcinoma involving the

liver was carried out. Their disease was confined to the liver at the time of trial entry. Patients may have already had an intrahepatic portacath in situ or have the drug administered via the hepatic artery by a femoral Seldinger approach.

The primary goal of this study was the determination of Maximal Tolerated Dose (MTD) and Dose-Limiting Toxicities (DLTs) of MMDX when administered via the hepatic artery.

Antitumor activity was documented in this study.

The starting dose was 100 mcg/m², corresponding to one third of the LD₁₀ in rats.

On a total of 18 registered patients, 13 received intra
5 hepatic artery (IHA) administration of MMDX.

Dose tested ranged from 100 mcg/m² to 800 mcg/m².

Results are available on 8 patients: 3 patients (6 cycles) at
~~100mcg/m², 3 patients (12 cycles) at 200mcg/m², and 2~~
patients (3 cycles) at 400 mcg/m².

10 Hematological toxicity

Grade 1 leucopenia was observed in 1 patient at 100 mcg/m² (1
cycle), 1 patient (2 cycles) at 200 mcg/m² and 2 patients (2
cycles) at 400 mcg/m². AGC were however always normal. Grade
1-2 thrombocytopenia occurred in 2 patients (5 cycles) at 200
15 mcg/m² and 1 patient (1 cycle) at 400 mcg/m² and were
considered tumor related (HCC patients). Max. grade 1 anemia
was reported in one patient at 200 mcg/m².

Non-hematological toxicity

The most frequently observed adverse events, attributable to
20 the study drug were nausea, vomiting and fatigue.

At 100 mcg/m², mild to moderate nausea and mild vomiting were
reported in one out of three patients (in 2 and 1 cycles
respectively); grade 1-2 fatigue was present in 2 patients (3
cycles).

25 At 200 mcg/m²: grade 2 nausea in 2 patients (3 cycles), grade
1-2 vomiting in 2 patients (4 cycles) and grade 2 fatigue in
2 patients (3 cycles).

At 400 mcg/m²: grade 2-3 nausea occurred in 2 patients (2
cycles), grade 2 vomiting in one cycle and grade 2 fatigue in
30 2 patients (3 cycles).

No other grade 3-4 events were reported.

Mild to moderate increase in transaminases (attributed to the
study drug) were observed at 200 mcg/m² (2/3 patients) and
400 mcg/m² (2 /2 patients). Grade 3 SGOT increase occurred in

one cycle at 400 mcg/m². The maximum transaminases elevation appeared during the first week after treatment. Grade 2 bilirubinemia were observed starting from 100 mcg/m², but were not considered due to the study drug.

5 Other severe, non tumor related, laboratory abnormalities consisted of 2. Grade 3 hyperglycemia observed in two patients treated at 200 mcg/m² (persisting from baseline in one diabetic patient).

Activity

10 Two objective tumor response were observed in liver at 200 mcg/m² in patients with HCC.

One patient had measurable liver disease at study entry followed by NMR (overall 17.75 cm²); after 2 IHA cycles, Partial Response (PR) was achieved (reduction by more than 15 86%); the PR was confirmed after the fourth IHA cycle and became Complete Response (CR) after the sixth IHA cycle; the patient went off therapy and, at the moment, he is relapse-free and in follow-up.

The second patient presented multiple liver lesions at 20 baseline (the bigger one was 6 cm diameter, evaluated by Ctscan). Also in this case, PR was observed after 2 IHA cycles and confirmed after the third IHA cycle (the bigger lesion was decreased by 50% in diameter). Despite extrahepatic tumor progression (bone), the patient received 25 another IHA treatment after which he was withdrawn from therapy. Two months later liver Ctscan was repeated and the

previous findings on the bigger lesions were confirmed while the smallest lesions were slightly increased.

These activity data show that the MMDX chemotherapy through 30 the hepatic artery is effective for patients with liver cancers at a MMDX dosage much lower than that employed by intravenous route, strongly reducing the dangerous systemic exposure and hence toxicity of MMDX.

CLAIMS

1. Use of methoxymorpholino doxorubicin (MMDX) in the preparation of a medicament formulated for intrahepatic administration in the treatment of a human liver tumour.

2. Use according to claim 1. wherein the liver tumor is a tumor primarily confined to the liver.

3. Use according to claim 2. wherein the tumor primarily confined to the liver is a hepatocellular carcinoma (HCC) or a cholangiocarcinoma.

4. Use according to claim 1. wherein the tumor is a liver metastasis.

5. Use according to any one of the preceeding claims wherein the intrahepatic administration of MMDX is via the hepatic artery.

6. Use according to any one of the preceeding claims wherein MMDX is administered as an infusion of from about 15 minutes to about 30 minutes every 4 weeks.

7. Use according to any one of the preceeding claims wherein MMDX is administered with an agent which remains selectively in a liver tumor after its injection through the hepatic artery.

8. Use according to claim 7 wherein the agent is iodized oil.

9. Use according to anyone of the preceeding claims wherein MMDX is administered in a dose ranging from about 100 mcg/m² to about 800 mcg/m².

10. Use according to claim 9 wherein the dose is 200 mcg/m².

1. A pharmaceutical composition which comprises as an active principle MMDX and a pharmaceutically acceptable agent which remains selectively in a liver tumor after its injection through the hepatic artery.

~~12. A pharmaceutical composition according to claim 11 wherein the agent is iodized oil.~~

10

13 Use of a pharmaceutical composition according to claim 11. or 12. for the treatment of a liver tumor.

15

14. Use of a pharmaceutical composition which comprises as an active principle MMDX and a pharmaceutically acceptable agent which remains selectively in a liver tumor after its injection through the hepatic artery, for the preparation of a medicament for use in the treatment of a liver tumor via intrahepatic administration.

20

15. Use according to claim 13 wherein the agent is iodized oil.


ABSTRACTUSE OF AN ANTHRACYCLINE DERIVATIVE FOR THE TREATMENT OF A
LIVER TUMOR


5

The present invention relates to the use of methoxymorpholino
doxorubicin for the treatment of a liver cancer; in
~~particular, it refers to the intrahepatic administration of~~

10

methoxymorpholino doxorubicin for use in the liver tumor
theraphy optionally in association with an agent which
remains selectively in liver tumor after its injection
through the hepatic artery.





48